NEW YORK – Liquid biopsy firm SeekIn said Friday that it has entered into a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live to expand the global accessibility of the firm's menu of cancer detection tests.
Beginning this month, OncoInv will distribute SeekIn's OncoSeek, SeekInCare, SeekInCure, and SeekInClarity assays across 12 countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania, and the UAE.
According to Shenzhen-based SeekIn, the companies formalized the agreement during the Inspire2Live Annual Congress in Amsterdam last month.
SeekIn's OncoSeek test is designed to screen for nine common cancer types using an assay to detect seven protein tumor markers. SeekInCare, SeekInCure, and SeekInClarity are intended for cancer early detection, recurrence monitoring, and treatment monitoring, respectively, and incorporate both shallow whole-genome sequencing and the aforementioned protein markers.
Apart from the immediate distribution agreement, the firms said that the collaboration also opens the doors to future research initiatives, opportunities for joint clinical trials, and the collaborative development of future cancer detection methods.
Financial terms of the deal were not disclosed.